ArcticZymes Technologies - Director's Dealing 2024

ArcticZymes Technologies - Primary insider trading

(Tromsø 06 November 2024) Frank Mathias, Chairman of the Board has on 06

November purchased 7.000 shares in ArcticZymes Technologies ASA for EUR 1.242

per share. Following this transaction holds Mr. Mathias 7.000 shares in the

company.

Børge Sørvoll, CFO has on 6 November purchased 5.000 shares in ArcticZymes

Technoloiges ASA for NOK 14.00 per share. Following this transaction holds Mr.

Sørvoll 100.428 shares and 280,000 options in the company.

This information is subject to the disclosure requirements in articles 19 of the

Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the

Norwegian Securities Trading Act.

For additional information, please contact

Børge Sørvoll

CFO

+4795290187

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing and commercialization of novel recombinant enzymes

for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.

Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large

portfolio of patents.

For more information, please visit the website: www.arcticzymes.com

AI assistant